Literature DB >> 26188075

Spatiotemporal dynamics of effector CD8+ T cell responses within the liver.

Donato Inverso1, Matteo Iannacone2.   

Abstract

CD8(+) T cells play a critical role in controlling hepatotropic viral infections, such as those caused by hepatitis B and hepatitis C viruses. The capacity of these cells to protect against such pathogens is mediated by antigen-experienced effector cells and relies on their ability to home to the liver, recognize pathogen-derived antigens, and deploy effector functions. Here, we review how dynamic imaging of hepatic effector CD8(+) T cell migration and function in mouse models of hepatitis B virus pathogenesis has recently revealed a unique and novel mode of adaptive immune surveillance. Circulating effector CD8(+) T cells initially arrest within liver sinusoids by docking onto adherent platelets and then actively crawl along the liver vasculature, probing hepatocytes for the presence of antigens by extending protrusions through the fenestrated sinusoidal endothelial cells. Hepatocellular antigen recognition and effector functions occur while CD8(+) T cells are still confined to the intravascular space and are inhibited by the pathologic processes that characterize liver fibrosis. A detailed understanding of the spatiotemporal dynamics of effector CD8(+) T cells within the liver is important for the rational design of targeted immunotherapeutic approaches for chronic liver infections. © Society for Leukocyte Biology.

Entities:  

Keywords:  antiviral immunity; intravital imaging; leukocyte trafficking; tissue immunosurveillance

Mesh:

Substances:

Year:  2015        PMID: 26188075      PMCID: PMC4673483          DOI: 10.1189/jlb.4MR0415-150R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  35 in total

1.  Two-photon imaging of lymphocyte motility and antigen response in intact lymph node.

Authors:  Mark J Miller; Sindy H Wei; Ian Parker; Michael D Cahalan
Journal:  Science       Date:  2002-05-16       Impact factor: 47.728

2.  The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection.

Authors:  Steven J Ray; Suzanne N Franki; Robert H Pierce; Snezhana Dimitrova; Victor Koteliansky; Andrew G Sprague; Peter C Doherty; Antonin R de Fougerolles; David J Topham
Journal:  Immunity       Date:  2004-02       Impact factor: 31.745

3.  Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo.

Authors:  A Hamann; D P Andrew; D Jablonski-Westrich; B Holzmann; E C Butcher
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

4.  Immunosurveillance of the liver by intravascular effector CD8(+) T cells.

Authors:  Luca G Guidotti; Donato Inverso; Laura Sironi; Pietro Di Lucia; Jessica Fioravanti; Lucia Ganzer; Amleto Fiocchi; Maurizio Vacca; Roberto Aiolfi; Stefano Sammicheli; Marta Mainetti; Tiziana Cataudella; Andrea Raimondi; Gloria Gonzalez-Aseguinolaza; Ulrike Protzer; Zaverio M Ruggeri; Francis V Chisari; Masanori Isogawa; Giovanni Sitia; Matteo Iannacone
Journal:  Cell       Date:  2015-04-16       Impact factor: 41.582

5.  CTL access to tissue antigen is restricted in vivo.

Authors:  K Ando; L G Guidotti; A Cerny; T Ishikawa; F V Chisari
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

6.  ELAM-1 is an adhesion molecule for skin-homing T cells.

Authors:  L J Picker; T K Kishimoto; C W Smith; R A Warnock; E C Butcher
Journal:  Nature       Date:  1991-02-28       Impact factor: 49.962

7.  Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B.

Authors:  Yasunari Nakamoto; Takashi Suda; Takashi Momoi; Shuichi Kaneko
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

Review 8.  Hepatic effector CD8(+) T-cell dynamics.

Authors:  Matteo Iannacone
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

9.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

Authors:  M K Maini; C Boni; C K Lee; J R Larrubia; S Reignat; G S Ogg; A S King; J Herberg; R Gilson; A Alisa; R Williams; D Vergani; N V Naoumov; C Ferrari; A Bertoletti
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

10.  Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  K Kakimi; T E Lane; S Wieland; V C Asensio; I L Campbell; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  4 in total

Review 1.  In vivo imaging of adaptive immune responses to viruses.

Authors:  Marco De Giovanni; Matteo Iannacone
Journal:  Curr Opin Virol       Date:  2017-12-26       Impact factor: 7.090

Review 2.  Immunobiology and pathogenesis of hepatitis B virus infection.

Authors:  Matteo Iannacone; Luca G Guidotti
Journal:  Nat Rev Immunol       Date:  2021-05-17       Impact factor: 53.106

3.  A spatial vascular transcriptomic, proteomic, and phosphoproteomic atlas unveils an angiocrine Tie-Wnt signaling axis in the liver.

Authors:  Donato Inverso; Jingjing Shi; Ki Hong Lee; Moritz Jakab; Shani Ben-Moshe; Shubhada R Kulkarni; Martin Schneider; Guanxiong Wang; Marziyeh Komeili; Paula Argos Vélez; Maria Riedel; Carleen Spegg; Thomas Ruppert; Christine Schaeffer-Reiss; Dominic Helm; Indrabahadur Singh; Michael Boutros; Sudhakar Chintharlapalli; Mathias Heikenwalder; Shalev Itzkovitz; Hellmut G Augustin
Journal:  Dev Cell       Date:  2021-05-25       Impact factor: 12.270

4.  In vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice.

Authors:  Raymond Reif; Ahmed Ghallab; Lynette Beattie; Georgia Günther; Lars Kuepfer; Paul M Kaye; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2016-12-20       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.